1466563-97-2Relevant academic research and scientific papers
SOLID FORMS OF ISOQUINOLINONE DERIVATIVES, PROCESS OF MAKING, COMPOSITIONS COMPRISING, AND METHODS OF USING THE SAME
-
Paragraph 00990, (2017/04/11)
Solid forms of chemical compounds that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein. Also provided herein are processes for preparing compounds, polymorphic forms, cocrystals, and amorphous forms thereof, and pharmaceutical compositions thereof.
Discovery of a Selective Phosphoinositide-3-Kinase (PI3K)-γ Inhibitor (IPI-549) as an Immuno-Oncology Clinical Candidate
Evans, Catherine A.,Liu, Tao,Lescarbeau, André,Nair, Somarajan J.,Grenier, Louis,Pradeilles, Johan A.,Glenadel, Quentin,Tibbitts, Thomas,Rowley, Ann M.,Dinitto, Jonathan P.,Brophy, Erin E.,O'Hearn, Erin L.,Ali, Janid A.,Winkler, David G.,Goldstein, Stanley I.,O'Hearn, Patrick,Martin, Christian M.,Hoyt, Jennifer G.,Soglia, John R.,Cheung, Culver,Pink, Melissa M.,Proctor, Jennifer L.,Palombella, Vito J.,Tremblay, Martin R.,Castro, Alfredo C.
, p. 862 - 867 (2016/10/06)
Optimization of isoquinolinone PI3K inhibitors led to the discovery of a potent inhibitor of PI3K-γ (26 or IPI-549) with >100-fold selectivity over other lipid and protein kinases. IPI-549 demonstrates favorable pharmacokinetic properties and robust inhibition of PI3K-γ mediated neutrophil migration in vivo and is currently in Phase 1 clinical evaluation in subjects with advanced solid tumors.
HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF PI3K-GAMMA MEDIATED DISORDERS
-
, (2015/11/10)
Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.
HETEROCYCLIC COMPOUNDS AND USES THEREOF
-
Paragraph 00657, (2015/04/22)
Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.
HETEROCYCLIC COMPOUNDS AND USES THEREOF
-
Paragraph 00707; 00708; 00709; 00748; 00749, (2015/04/22)
Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.
HETEROCYCLIC COMPOUNDS AND USES THEREOF
-
, (2013/10/22)
Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.
